A Phase 1, Randomized, Placebo- and Active-Controlled, 4-Period Crossover, Proof of Concept Glucose Clamp Study to Compare the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single Doses of TAK-329 With a Single Dose of a Subcutaneously-Injected Rapid-Acting Insulin Analog in Subjects With Type 1 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Insulin; TAK 329
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 10 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
- 10 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.